이중 인크레틴 작용제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global dual incretin agonists market size is expected to reach USD 77.14 Billion in 2034 from USD 39.01 Billion in 2025, growing at a CAGR of 7.87 during 2026-2034.This market is witnessing remarkable expansion as innovative therapies transform the treatment landscape for type 2 diabetes and obesity. Dual incretin agonists offer improved glucose regulation, enhanced weight reduction, and better metabolic outcomes by targeting multiple hormonal pathways simultaneously. Rising prevalence of metabolic disorders, sedentary lifestyles, and increasing obesity rates are significantly contributing to growing demand for these advanced therapeutic solutions.

Extensive pharmaceutical research, successful clinical trial outcomes, and growing physician confidence are accelerating commercial adoption worldwide. Healthcare providers increasingly recognize the benefits of dual incretin therapies in improving glycemic control while supporting cardiovascular and metabolic health. Expanding regulatory approvals, improved patient access programs, and rising healthcare expenditure are creating a favorable environment for continued industry expansion.

Future prospects remain exceptionally promising as pharmaceutical companies develop next-generation metabolic therapies with enhanced efficacy and improved safety profiles. Personalized treatment strategies, combination therapies, and long-acting formulations are expected to further improve patient outcomes. Increasing investments in obesity management, diabetes prevention programs, and metabolic disease research will continue driving sustained long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug

• Tirzepatide
• Survodutide
• Others

By Disease Indication

• Type 2 Diabetes
• Obesity
• MASH/NASH
• Others

By Age Group

• Pediatric
• Adults

By Type

• Branded
• Generic

By Route of Administration

• Subcutaneous
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Altimmune Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck & Co. Inc., OPKO Health Inc., Viking Therapeutics Inc., Zealand Pharma A/S

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Tirzepatide Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Survodutide Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Type 2 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Obesity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. MASH/NASH Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Type
• 7.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Distribution Channel
• 9.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL DUAL INCRETIN AGONISTS MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Drug
  • 10.2.2 By Disease Indication
  • 10.2.3 By Age Group
  • 10.2.4 By Type
  • 10.2.5 By Route Of Administration
  • 10.2.6 By Distribution Channel
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Drug
  • 10.3.2 By Disease Indication
  • 10.3.3 By Age Group
  • 10.3.4 By Type
  • 10.3.5 By Route Of Administration
  • 10.3.6 By Distribution Channel
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Drug
  • 10.4.2 By Disease Indication
  • 10.4.3 By Age Group
  • 10.4.4 By Type
  • 10.4.5 By Route Of Administration
  • 10.4.6 By Distribution Channel
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Drug
  • 10.5.2 By Disease Indication
  • 10.5.3 By Age Group
  • 10.5.4 By Type
  • 10.5.5 By Route Of Administration
  • 10.5.6 By Distribution Channel
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Drug
  • 10.6.2 By Disease Indication
  • 10.6.3 By Age Group
  • 10.6.4 By Type
  • 10.6.5 By Route Of Administration
  • 10.6.6 By Distribution Channel
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL DUAL INCRETIN AGONISTS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Altimmune Inc
  • 12.2.2 Boehringer Ingelheim International GmbH
  • 12.2.3 Eli Lilly And Company
  • 12.2.4 Hanmi Pharmaceutical Co. Ltd
  • 12.2.5 Innovent Biologics Inc
  • 12.2.6 Jiangsu Hengrui Pharmaceuticals Co. Ltd
  • 12.2.7 Merck & Co. Inc
  • 12.2.8 OPKO Health Inc
  • 12.2.9 Viking Therapeutics Inc
  • 12.2.10 Zealand Pharma A/S